BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 23049789)

  • 1. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.
    Antelo M; Balaguer F; Shia J; Shen Y; Hur K; Moreira L; Cuatrecasas M; Bujanda L; Giraldez MD; Takahashi M; Cabanne A; Barugel ME; Arnold M; Roca EL; Andreu M; Castellvi-Bel S; Llor X; Jover R; Castells A; Boland CR; Goel A
    PLoS One; 2012; 7(9):e45357. PubMed ID: 23049789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
    Goel A; Xicola RM; Nguyen TP; Doyle BJ; Sohn VR; Bandipalliam P; Rozek LS; Reyes J; Cordero C; Balaguer F; Castells A; Jover R; Andreu M; Syngal S; Boland CR; Llor X
    Gastroenterology; 2010 May; 138(5):1854-62. PubMed ID: 20102720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.
    Garre P; Martín L; Bando I; Tosar A; Llovet P; Sanz J; Romero A; de la Hoya M; Díaz-Rubio E; Caldés T
    Fam Cancer; 2014 Mar; 13(1):109-19. PubMed ID: 24061861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
    Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
    World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.
    de Maat MF; Narita N; Benard A; Yoshimura T; Kuo C; Tollenaar RA; de Miranda NF; Turner RR; van de Velde CJ; Morreau H; Hoon DS
    Am J Pathol; 2010 Nov; 177(5):2347-56. PubMed ID: 20952593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
    Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
    Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
    Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
    Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.